ArticleBlood cancer journal2025

Allo-HCT refined ELN 2022 risk classification: validation of the Adverse-Plus risk group in AML patients undergoing allogeneic hematopoietic cell transplantation within the Spanish Group for Hematopoietic Cell Transplantation (GETH-TC).

Carlos Jiménez-Vicente et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.